We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Benitec’s Pain Program Validated by Independent Study
News

Benitec’s Pain Program Validated by Independent Study

Benitec’s Pain Program Validated by Independent Study
News

Benitec’s Pain Program Validated by Independent Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Benitec’s Pain Program Validated by Independent Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Benitec Ltd, has announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

This independent research was published in the prestigious international scientific journal Human Gene Therapy.

Using a form of Benitec's gene silencing technology in a rat model, the researchers silenced a key gene associated with pain and achieved a significant reduction in pain without side effects.

“Currently, treatment of neuropathic pain is still a challenge, as it is insensitive to traditional pain drugs and surgical interventions,” the researchers state in their paper. They concluded, “These results support the potential use of shRNA expression vectors as a gene therapy approach to neuropathic pain..."

Dr Peter French, CEO of Benitec said, “Remarkably the independent researchers on this study utilized an almost identical experimental design to that currently being used in our own in-house program. Their finding of significant efficacy with no adverse effects in the preclinical model has the potential to substantially accelerate our efforts in bringing a novel pain therapeutic to the clinic supported by our dominant patent position in the underlying DNA-directed RNAi technology."

Advertisement